Prevalence of nevirapine-associated resistance mutations after single dose prophylactic treatment among antenatal clinic attendees in North Rift Kenya

AIDS Research and Human Retroviruses

Volumn 24, Issue 12, 2008, Pages 1555-1559

  Kiptoo, Michael ^a,b   Ichimura, Hiroshi ^c   Wembe, Raphael L ^a,c   Ng'Ang'a, Zipporah ^b   Mueke, Jones ^b   Kinyua, Joyceline ^a   Lagat, Nancy ^a   Okoth, Fredrick ^a   Songok, E M ^a,b,d  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b KENYATTA UNIVERSITY   (Kenya)

^c KANAZAWA UNIVERSITY   (Japan)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DISEASE TRANSMISSION; DOSE RESPONSE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; PRENATAL CARE; PREVALENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANTI-HIV AGENTS; CHEMOPREVENTION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; KENYA; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NEVIRAPINE; PHYLOGENY; POLYMERASE CHAIN REACTION; PROVIRUSES; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY;

EID: 58149133691     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2008.0018     Document Type: Article

References (15)

1. Wiktor SZ, Ekpini E, Karon JM, et al.: Short course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d voire: A randomised trial. Lancet 1999;353(9155):781-785.
2. Guay LA, Musoke P, Fleming T, et al.: Intrapartum and neonatal single dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999;354(9181):795 802.
3. Jackson JB, Becker-Pergola G, Guay LA, et al.: Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000;14(11):F111-F115.
4. Toni TD, Masquelier B, Lazaro E, et al.: Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission. AIDS Res Hum Retroviruses 2005;21:1031-1034.
5. President Emergency Program For AIDS Relief (PEPFAR) http://www.pepfar. gov.
6. Ministry of Health, NASCOP (National AIDS/STI Control Programme, 2002): National Guidelines: Prevention of Mother-To-Child HIV/AIDS Transmission (PMTCT), 2nd ed., p. 2.
7. Ndembi N, Takehisa J, Zekeng L, et al.: Genetic diversity of HIV type 1 in rural eastern Cameroon. J Acquir Immune Defic Syndr 2004;37:1641-1650.
8. Thomson JD, Higgins DG, and Gibson TJ: CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-4680.
9. Koizumi Y, Ndemi N, Miyashita M, et al.: Emergence of antiretroviral therapy resistance-associated primary mutations among drug-naive HIV-1-infected individuals in rural Western Cameroon. J Acquir Immune Defic Syndr 2006;43:15-22.
10. Lihana RW, Khamadi SA, Kiptoo MK, et al.: HIV-1 Subtypes among STI patients in Nairobi: A genotypic study based on partial pol gene sequencing. AIDS Res Hum Retroviruses 2006;22(11):1172-1177.
11. Khamadi SA, Ochieng W, Lihana RW, et al.: HIV type 1 subtypes in circulation in northern Kenya. AIDS Res Hum Retroviruses 2005;21(9):810-814.
12. Chew CB, Potter SJ, Wang B, et al.: Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol 2005;33:206-216.
13. Lwembe R, Ochieng W, Panikulam A, et al.: Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. J Med Virol 2007;79(7):865-872.
14. Eshleman HS, Mracna M, Guay AL, et al.: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15(15):1951-1957.
15. Babic DZ, Zelnikar M, Seme K, et al.: Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naive patients in Slovenia, 2000-2004. Virus Res 2006;118(1-2):156-163.